Literature DB >> 9165630

Substance use disorder and the early course of illness in schizophrenia and affective psychosis.

B Kovasznay1, J Fleischer, M Tanenberg-Karant, L Jandorf, A D Miller, E Bromet.   

Abstract

The relationship between a history of substance use disorder and the early course of psychotic illness was examined in 96 subjects with schizophrenia and 106 subjects with affective psychosis followed in the Suffolk County Mental Health Project, a longitudinal study of first-admission psychosis. Subjects received a structured diagnostic interview and clinical ratings at baseline assessment and again 6 months later. The 6-month assessment included information about treatment received during the interval. A lifetime history of substance use disorder was associated with worse clinical functioning at 6 months for schizophrenia subjects, but not for those with affective psychosis. There were no significant associations of substance use disorder with type of treatment during the interval or with self-reported compliance with medication. Schizophrenia subjects were more likely than subjects with affective psychosis to report cannabis use during the interval and to meet criteria for cannabis use disorder.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9165630     DOI: 10.1093/schbul/23.2.195

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  36 in total

Review 1.  Improving the quality of the cannabis debate: defining the different domains.

Authors:  J Strang; J Witton; W Hall
Journal:  BMJ       Date:  2000-01-08

2.  Olanzapine vs. risperidone in patients with first-episode schizophrenia and a lifetime history of cannabis use disorders: 16-week clinical and substance use outcomes.

Authors:  Serge Sevy; Delbert G Robinson; Suzanne Sunday; Barbara Napolitano; Rachel Miller; Joanne McCormack; John Kane
Journal:  Psychiatry Res       Date:  2011-06-01       Impact factor: 3.222

3.  A qualitative study of career exploration among young adult men with psychosis and co-occurring substance use disorder.

Authors:  Alison Luciano; Elizabeth A Carpenter-Song
Journal:  J Dual Diagn       Date:  2014

Review 4.  [Pharmacotherapy of schizophrenia and comorbid substance use disorder. A systematic review].

Authors:  T Wobrock; R D'Amelio; P Falkai
Journal:  Nervenarzt       Date:  2008-01       Impact factor: 1.214

Review 5.  The Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis.

Authors:  Britta Hahn
Journal:  Schizophr Bull       Date:  2018-01-13       Impact factor: 9.306

6.  Are cannabis use disorders associated with an earlier age at onset of psychosis? A study in first episode schizophrenia.

Authors:  Serge Sevy; Delbert G Robinson; Barbara Napolitano; Raman C Patel; Handan Gunduz-Bruce; Rachel Miller; Joanne McCormack; Beth S Lorell; John Kane
Journal:  Schizophr Res       Date:  2010-05-14       Impact factor: 4.939

7.  The Effect of Substance Use on 10-Year Outcome in First-Episode Psychosis.

Authors:  Melissa A Weibell; Wenche Ten Velden Hegelstad; Bjørn Auestad; Jørgen Bramness; Julie Evensen; Ulrik Haahr; Inge Joa; Jan Olav Johannessen; Tor Ketil Larsen; Ingrid Melle; Stein Opjordsmoen; Bjørn Rishovd Rund; Erik Simonsen; Per Vaglum; Thomas McGlashan; Patrick McGorry; Svein Friis
Journal:  Schizophr Bull       Date:  2017-07-01       Impact factor: 9.306

8.  Predictors of psychosis remission in psychotic disorders that co-occur with substance use.

Authors:  Carol L M Caton; Deborah S Hasin; Patrick E Shrout; Robert E Drake; Boanerges Dominguez; Sharon Samet; Bella Schanzer
Journal:  Schizophr Bull       Date:  2006-07-27       Impact factor: 9.306

Review 9.  Substance use disorder among people with first-episode psychosis: a systematic review of course and treatment.

Authors:  Jennifer P Wisdom; Jennifer I Manuel; Robert E Drake
Journal:  Psychiatr Serv       Date:  2011-09       Impact factor: 3.084

10.  Demographic and clinical correlates of substance abuse comorbidity in schizophrenia.

Authors:  Tapas K Aich; Vinod K Sinha; Christoday R J Khess; Shailja Singh
Journal:  Indian J Psychiatry       Date:  2004-04       Impact factor: 1.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.